Roche: FDA Approves Vabysmo To Treat Two Vision-threatening Retinal Conditions
31/1 09:19
(RTTNews) - Roche (RHHBY) said FDA has approved Vabysmo (faricimab-svoa) for the treatment of neovascular or "wet" age-related macular degeneration and diabetic macular edema. Neovascular AMD and DME are two leading causes of vision loss worldwide. The company noted that Vabysmo...